WASHINGTON (AP) - The Food and Drug Administration is adding its strongest warning to the label for Plavix after reports that some patients cannot process the blood thinning drug.
The FDA says certain patients with a genetic variation cannot metabolize the drug, putting them at increased risk for heart attack and stroke.
Patients can determine if they don't respond to Plavix by taking a genetic test. The FDA recommends non-responding patients take other blood thinners, such as aspirin.
The new Plavix warning will appear within a black box, the FDA's most severe warning.
Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb. With global sales of $8.6 billion in 2008, it was the world's second-best selling drug behind Pfizer's cholesterol drug Lipitor.
Web Search powered by YAHOO!
|
LifestylesLifestyles
FDA warns some patients cannot process Plavix
WASHINGTON (AP) - The Food and Drug Administration is adding its strongest warning to the label for Plavix after reports that some patients cannot process the blood thinning drug.
By:
|
WNCT
Published: March 12, 2010
Published: March 12, 2010
Email
Facebook
Google
Twitter
Favorites
MoreAdvertisement
View More:
Bristol,
Bristol-Myers Squibb,
Food And Drug Administration,
Health_Medical_Pharma,
Heart Attack,
Lipitor,
Pfizer,
Plavix,
Sanofi-Aventis,
Stroke,
Usd,
Washington
Not what you're looking for? Try our quick search:
Reader Comments
*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.Deal of the Day
Advertisement
Interactive Radar
Advertisement
Featured Blogger
Reel Reviews
Updated: 02/10/2012
Nine On Your Side's Phillip Sayblack shares his take on the latest movie and dvd releases.
More Posts by Reel Reviews
Hot Topics on WNCT.com
Advertisement
Advertisement